Rapid Micro Biosystems (RPID) Q2 2026 Earnings Call Transcript
Rapid Micro Biosystems (RPID) reported Q2 2026 revenue of $8.1M, up 10.9% YoY, with product revenue $5.3M and service revenue $2.8M. Recurring revenue was $5.0M, up 14.3% YoY, and gross margin was 15.0%. Net loss was $12.9M ($0.27/share). Full-year revenue guidance was reaffirmed at $37M to $41M.
How this was made
The 30-second read
Why it matters
The most tradable elements are the reaffirmed FY 2026 revenue range, the explicit Q3 2026 revenue floor tied to system placements, record gross margin and service margin, and management commentary on cash headwinds and potential MilliporeSigma fulfillment timing delays.
Market read
Investors get a full set of operating KPIs (consumables, recurring revenue, placements/validations) plus margin and guidance updates that can drive expectation changes for 2026 growth and 2028 cash-flow path.
What to watch
Product margin remains negative (-3%) and the company’s cash position and expense actions depend on execution of the August efficiency program and milestone-based access to the Trinity Capital tranche.
Background
This is the Q2 2026 earnings call transcript for Rapid Micro Biosystems, covering revenue mix, margins, system placements/validations, guidance, and cash usage drivers.
Ticker impact
Rapid Micro Biosystems reported Q2 2026 revenue of $8.1M, record gross margin 15%, and reaffirmed FY 2026 guidance of $37M to $41M.
Moderate upside bias for the next few sessions if investors focus on margin expansion and recurring revenue growth; downside risk if cash usage concerns dominate.
The call discloses multiple fresh operating datapoints (record gross margin, consumable growth, recurring revenue mix, system validation guidance) that can re-rate expectations, while also highlighting cash headwinds and potential MilliporeSigma fulfillment delays.
Market effects
Signals improving unit economics in microbial quality control automation and potential scaling of consumables and validation services in biomanufacturing workflows.
Management cites activity across North America, Europe, and Asia, suggesting demand is not confined to a single geography.
Enterprise deployments and the MilliporeSigma collaboration could influence broader adoption of automated microbial quality control globally.
Counterpoint
Margin improvement may not translate into near-term profitability if cash burn persists and working-capital headwinds or fulfillment delays extend.
Key entities
- companyRapid Micro Biosystems, Inc.
Reported Q2 2026 results, record gross margin, and reaffirmed FY 2026 and Q3 2026 revenue guidance; discussed cash usage and collaboration timing.
- partnerMilliporeSigma
Collaboration referenced as contributing to system placements, with management expecting fulfillment timing to extend beyond calendar year 2026.
- financingTrinity Capital facility
Company expects to achieve milestones to access a $10 million tranche later in 2026.
